Yesterday Merck announced to its employees that it’s going through another round of contraction and rearrangement. They don’t seem to have announced it to anyone else, though, so here are the details as I have them:
The North Wales, PA site is being closed (the screening operations there are moving to Kenilworth). New Jersey discovery chemistry (Kenilworth and Rahway) is being cut by 20%, and Rahway’s med-chem is entirely moving to Kenilworth over the next few months. Disease area biology in Kenilworth is shutting down (not sure what the ramifications of that one might be). I’m told that some people will be offered a chance to move to the Boston or Bay area sites, and all of these decisions will be made by the end of September. And apparently they’ve also told everyone that more changes will be coming in the next few weeks, so I’m sure that’s calmed everything down as well.
Anyone with more details is welcome to add them in the comments, but that’s what I have now. . .
Update: comment from Merck, which is about what you’d expect.